Accendra Health Q4 revenue $709M; GAAP loss narrows to $9.4M; completes P&HS sale

ACCENDRA HEALTH INC/VA/

2025-FY EPS reported -$14.31 revenue$2,762,032,000

Revenue from continuing ops $709M (up 2% YoY); full-year revenue $2.76B (+3% YoY).
GAAP loss from continuing ops improved to $9.4M from $331.9M in Q4 2024.
Adjusted net income $16.7M ($0.21/share) vs $25.0M ($0.32) prior year.
Adj. EBITDA $90M vs $102.5M; free cash flow $18.3M vs $30.1M.
Completed sale of Products & Healthcare Services on Dec 31, 2025; focusing on cost control and balance sheet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.